BioMed Nexus

Lilly Crushes Q1 with $19.8B in Revenue and Raises Guidance by $2B • But Foundayo's Launch Is Slower Than Expected

Mounjaro hit $8.7B (+125%). Zepbound hit $4.1B (+79%). Combined GLP-1 revenue: $12.8B. Revenue beat estimates by more than $2B. But Foundayo logged just 3,707 scripts in Week 2 versus analyst expectations of 8,000. Lilly says it's early.

Chiesi Pays $1.9B for KalVista's Rare Disease Drug • AstraZeneca Sees $80B by 2030 • Lilly Reports Today

The Italian pharma bets big on Ekterly for hereditary angioedema. AstraZeneca beat Q1 estimates and doubled down on its 2030 revenue target. AbbVie entered the KRAS race. And Lilly reports before the bell this morning.

The FDA Wants to Watch Your Clinical Trial in Real Time • Novartis Feels the Patent Cliff • Lilly Inks Its Sixth Deal

AstraZeneca and Amgen are already piloting real-time data sharing with the FDA. Novartis missed on Q1 as Entresto fell 42%. Lilly partnered with Profluent on AI gene editing for $2.25B. And Lilly reports tomorrow.

Lilly Makes Its Fifth Acquisition of 2026 — That's Nearly $20B in Deals in Three Months

Ajax Therapeutics brings a first-in-class blood cancer drug to Lilly's expanding oncology pipeline. Meanwhile, Regeneron became the last of 17 pharma companies to sign an MFN deal. All 17 are now in. Lilly reports earnings tomorrow.

Sun Pharma Acquires Organon for $11.75B • Trump Signs Psychedelic Therapy Executive Order • Lilly Earnings Wednesday

India's largest drugmaker takes over the Merck spinoff in one of the biggest pharma deals of 2026. The FDA issued its first psychedelic CNPVs. Daiichi Sankyo delayed earnings to model tariff exposure. And Lilly reports on Wednesday.

Foundayo Shows 57% Lower Death Risk in Landmark Diabetes Trial • Lilly Plans Diabetes Filing This Quarter

ACHIEVE-4 is the data Lilly needed. CV safety confirmed, A1C and weight superiority over insulin, and an all-cause mortality signal that could reshape the label. Plus: the week in review and a big earnings week ahead.

Medicare Shelves Its GLP-1 Coverage Plan After Insurers Balk • FDA Approves Merck's HIV Drug Ahead of Schedule

CVS declined and UnitedHealth raised concerns about the BALANCE program. The Bridge interim program is extended through 2027. Merck's Idvynso is the first non-INSTI two-drug HIV regimen to beat Biktarvy. J&J kicks off earnings season above $15B.

Daraxonrasib Hits 58% Response Rate in First-Line Pancreatic Cancer Combination • Revolution Secures ASCO Plenary

The combo with chemo nearly doubled the monotherapy response rate in untreated patients. Revolution also unveiled RM-055, a next-gen catalytic inhibitor that overcomes resistance. Full Phase 3 data gets the ASCO plenary slot on May 31.

Lilly Pays $3.25B Upfront for In Vivo CAR-T Maker Kelonia • Revolution's AACR Data Drops Today

Lilly's second in vivo CAR-T deal of the year brings the total potential value to $7B. The company that nearly ran out of cash three times just landed a blockbuster exit. Revolution Medicines presents combination pancreatic cancer data at AACR today. Q1 obesity deal commitments hit $22B.

Kailera Breaks the Biotech IPO Record at $625M • Foundayo Logs 1,390 Scripts in Its First Week • AACR Is Live

The obesity drugmaker surged 63% on its first day of trading. Foundayo's first prescription data is in. Revolution's late-breaking pancreatic cancer data drops tomorrow at AACR. And pharma earnings season starts this week.

Revolution Medicines Raises $2B in the Largest Biopharma Follow-On Ever • Novartis CEO Joins Anthropic Board

The pancreatic cancer data was so strong that Revolution upsized from $750M to $2B in two days. Novartis CEO Narasimhan is the first pharma exec on Anthropic's board, giving the Trust a governing majority. AACR 2026 starts today.

BMS and Bain Unveil Beeline Medicines with $300M and 5 Immune Drugs • Takeda Prunes Another Partnership

Beeline emerges from stealth with afimetoran in Phase 2 lupus. Takeda cuts ties with Veritas In Silico on mRNA. Astellas closes its Universal Cells site. And pharma Q1 earnings season starts next week.

Revolution Medicines Surges 41% and Raises $750M to Commercialize Its Pancreatic Cancer Drug

RVMD hit an all-time high after nearly doubling survival in Phase 3. The company launched a $750M equity offering, plans to file under the CNPV program, and will present full data at ASCO 2026. Analyst targets raised to $147 to $165.

A Pancreatic Cancer Drug Just Nearly Doubled Survival in a Phase 3 Trial

Revolution Medicines' daraxonrasib hit all endpoints in second-line metastatic pancreatic cancer. Median OS: 13.2 months vs. 6.7 months. Hazard ratio 0.40. Wall Street is calling it unprecedented. A first-line trial is already enrolling.

FDA Rejects Replimune's Melanoma Drug Again, and the Company May Walk Away | The Week Ahead

RP1 got a second complete response letter on Friday. Replimune says development is no longer viable without accelerated approval. Biopharma raised $22.8B in Q1. Plus a full look at the week ahead.

PhRMA's Longest-Serving CEO Is Stepping Down • FDA Proposes a Faster Path to Phase 1

Steve Ubl exits after a decade navigating drug pricing wars and the pandemic. The FDA wants an expedited IND pathway to speed Phase 1 trials. Plus: the week in review.

Sanofi's Dupixent Successor Hits in Asthma, Misses in Eczema • AbbVie Lists Humira on TrumpRx at 86% Off

Lunsekimig met primary endpoints in asthma and nasal polyps but missed in atopic dermatitis. AbbVie's 86% Humira discount signals how pharma is responding to Section 232 tariffs. Foundayo rollout continues.

Gilead Makes Its Third Acquisition in 6 Weeks • Neurocrine Pays $2.9B for Prader-Willi Drug

Gilead pays up to $5B for ADC specialist Tubulis. That's $15B in 3 deals since late February. Neurocrine enters rare metabolic disease with Soleno's Vykat XR. The M&A machine keeps running.

Lilly's Oral GLP-1 Foundayo Is Approved and Shipping • Anthropic Pays $400M for a Biotech AI Team

The FDA approved orforglipron on April 1 under the CNPV program. It's already shipping through LillyDirect at $149/month. Anthropic acquired a 10-person biotech AI startup. Takeda dumps Denali. The global pipeline contracts for the first time in 30 years.

Trump Imposes 100% Tariffs on Patented Pharmaceuticals

The Section 232 order is the most significant trade action to hit pharma in decades. Generics and biosimilars are exempt. Companies with MFN pricing deals pay zero. A separate investigation into medical devices is active. Orforglipron in 4 days.

Q1 Ends with $46.8B in M&A and a 7% XBI Surge • Immunovant TED Trial Misses

Biopharma spent nearly $47B on 19 deals in Q1. The XBI surged 7% on the last day of the quarter. Immunovant's batoclimab missed in both Phase 3 TED studies. Orforglipron in 7 days.

Novo Launches Wegovy Subscriptions, Cuts 400 Manufacturing Jobs, and Medtronic Expands Its Surgical Robot

Novo's new pricing model signals where obesity is headed. 400 jobs gone at the ex-Catalent site. Medtronic's Stealth Axis cleared for cranial and ENT. Orforglipron in 8 days.

$13.4B in M&A Drops in a Single Day • Lilly Enters Sleep Medicine

Lilly pays $7.8B for Centessa's narcolepsy pipeline. Biogen pays $5.6B for Apellis at a 140% premium. And orforglipron is 9 days away.

Lilly’s $2.75B AI Deal Resets Drug Discovery

Largest AI drug deal ever. Takeda cuts 634 jobs. White House circulates drug pricing legislation.

First Gene Therapy for LAD-I Approved • ACC.26 Reshapes Cardiology

Rocket clears FDA with Kresladi. Two NEJM trials shift PE and AFib treatment. Orforglipron decision in 11 days.